



PTO/SB/21 (09-04)

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/089,525
Filing Date	October 7, 2002
First Named Inventor	Marth, Jamey D.
Art Unit	1635
Examiner Name	Ashen, Jonathan Benjamin
Attorney Docket Number	19452A-000610US

**ENCLOSURES (Check all that apply)**

- |  |   |  |
|--|---|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Reply to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____<br><input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):<br>Form PTO/SB/08A (1 pg.);<br>Form PTO/SB/08B (2 pgs.);<br>ISR (3 pgs.);<br>References AA - AU (21);<br>Return Postcard |
|--|---|--|

Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
---------	--

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Townsend and Townsend and Crew LLP
Signature	
Printed name	Nicholas V. Sherbina
Date	June 16, 2005

Reg. No.	54,443
----------	--------

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature	
Typed or printed name	J.M. Smolen

Date	June 16, 2005
------	---------------

JUN 20 2005

PTO/SB/17 (12-04)

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL

## For FY 2005

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$ 180)

## Complete if Known

Application Number	10/089,525
Filing Date	October 7, 2002
First Named Inventor	Marth, Jamey D.
Examiner Name	Ashen, Jonathan Benjamin
Art Unit	1635
Attorney Docket No.	19452A-000610US

## METHOD OF PAYMENT (check all that apply)

☐ Check   ☐ Credit Card   ☐ Money Order   ☐ None   ☐ Other (please identify): \_\_\_\_\_  
☒ Deposit Account   Deposit Account Number: 20-1430   Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below   ☐ Charge fee(s) indicated below, except for the filing fee  
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17   ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

## FEE CALCULATION

## 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES Small Entity		SEARCH FEES Small Entity		EXAMINATION FEES Small Entity		Fees Paid (\$)
	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

## 2. EXCESS CLAIM FEES

Fee Description	Small Entity	
	Fee (\$)	Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

Total Claims   Extra Claims   Fee (\$)   Fee Paid (\$)   Multiple Dependent Claims  
 \_\_\_\_\_ -20 or HP = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_   Fee (\$)   Fee Paid (\$)  
 HP = highest number of total claims paid for, if greater than 20  
Indep. Claims   Extra Claims   Fee (\$)   Fee Paid (\$)  
 \_\_\_\_\_ -3 or HP = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_  
 HP = highest number of independent claims paid for, if greater than 3

## 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____ - 100 = _____	_____ / 50 = _____	_____ (round up to a whole number)	x _____ = _____	

## 4. OTHER FEE(S)


Non-English Specification, \$130 fee (no small entity discount)

Other: Submission of Information Disclosure Stmt

Fees Paid (\$)

180

## SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	54,443	Telephone	206-467-9600
Name (Print/Type)	Nicholas V. Sherbina			Date	June 16, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 16, 2005



By: [Signature]

**PATENT**  
Attorney Docket No.: 19452A-000610US  
Client Reference No.: SD 1999-158

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

MARTH, Jamey D.  
and ELLIES, Lesley G.

Application No.: 10/089,525

Filed: October 7, 2002

For: PREVENTION OF  
ATHEROSCLEROSIS AND  
UNDESIREB BLOOD CLOTTING BY  
REDUCING VON WILLEBRAND  
FACTOR

Customer No.: 20350

Confirmation No. 9242

Examiner: Ashen, Jonathan Benjamin

Art Unit: 1635

**INFORMATION DISCLOSURE  
STATEMENT UNDER  
37 CFR §1.97 and §1.98**

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Further to the Amendment filed on June 10, 2005 in response to the Office Action mailed February 10, 2005, Applicants submit an Information Disclosure Statement Under 37 CFR §1.97 and § 1.98.

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner.

06/21/2005 SHASSEN1 00000023 201430 10089525

01 FC:1806 180.00 DA

Copies of the references are enclosed. Also enclosed is a copy of the International Search Report corresponding to the PCT application.


It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.


Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Nicholas V. Sherbina  
Reg. No. 54,443

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
NVS:mmm



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/089,525	
			Filing Date	October 7, 2002	
			First Named Inventor	Marth, Jamey D.	
			Art Unit	1635	
			Examiner Name	Ashen, Jonathan Benjamin	
Sheet	1	of	3	Attorney Docket Number	19452A-000610US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AA	PCT	WO 98/54365		12/03/1998	Cytel Corporation		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.




Substitute for form 1449A&B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/089,525	
			Filing Date	October 7, 2002	
			First Named Inventor	Marth, Jamey D.	
			Art Unit	1635	
			Examiner Name	Ashen, Jonathan Benjamin	
Sheet	2	of	3	Attorney Docket Number	19452A-000610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AB	CARVER-MOORE, K. <i>et al.</i> , "Low levels of erythroid and myeloid progenitors in thrombopoietin- and <i>c-mpl</i> -deficient mice," <i>Blood</i> , 88(3):803-808 (Aug. 1, 1996)	
	AC	CROCKER, P. <i>et al.</i> , "The potential role of sialoadhesin as a macrophage recognition molecule in health and disease," <i>Glycoconj. J.</i> , 14:601-609 (1997)	
	AD	GILL, J. <i>et al.</i> , "The effect of ABO blood group on the diagnosis of von Willebrand disease," <i>Blood</i> , 69(6):1691-1695 (June 1987)	
	AE	GINSBURG, D. and BOWIE, E.J., "Molecular genetics of von Willebrand disease," <i>Blood</i> , 79(10):2507-2529 (May 15, 1992)	
	AF	GURNEY, A. <i>et al.</i> , "Thrombocytopenia in <i>c-mpl</i> -deficient mice," <i>Science</i> , 265:1445-1447 (Sept. 2, 1994)	
	AG	HALL, R. <i>et al.</i> , "The frequencies of ABO blood groups and of secretors of ABH group substances in peripheral arteriosclerosis," <i>Atherosclerosis</i> , 14:241-246 (1971)	
	AH	KITAGAWA, H. and PAULSON, J. <i>et al.</i> , "Cloning of a novel $\alpha$ 2,3-sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups," <i>J. Biol. Chem.</i> , 269(2):1394-1401 (Jan. 14, 1994)	
	AI	LECINE, P. <i>et al.</i> , "Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes," <i>Blood</i> , 92(5):1608-1616 (Sept. 1, 1998)	
	AJ	MEADE, T.W. <i>et al.</i> , "Haemostatic function and cardiovascular death: Early results of a prospective study," <i>The Lancet</i> , 1:1050-1053 (May 17, 1980)	
	AK	MOHLKE, K. <i>et al.</i> , " <i>Mvwl</i> , a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase," <i>Cell</i> , 96:111-120 (Jan. 8, 1999)	
	AL	NICHOLS, W. and GINSBURG, D., "von Willebrand Disease," <i>Medicine</i> , 76(1):1-20 (1997)	
	AM	OKAJIMA, T. <i>et al.</i> , "Molecular cloning of a novel $\alpha$ 2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids," <i>J. Biol. Chem.</i> , 274(17):11479-11486 (April 23, 1999)	
	AN	ORSTAVIK, K. <i>et al.</i> , "Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor," <i>Blood</i> , 73(4):990-993 (March 1989)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/089,525	
			Filing Date	October 7, 2002	
			First Named Inventor	Marth, Jamey D.	
			Art Unit	1635	
			Examiner Name	Ashen, Jonathan Benjamin	
Sheet	3	of	3	Attorney Docket Number	19452A-000610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AO	RUGGERI, Z. and ZIMMERMAN, T., "Variant von Willebrand's disease: Characterization of two subtypes by analysis of multimetric composition of factor VIII/von Willebrand factor in plasma and platelets," <i>J. Clin. Invest.</i> , 65:1318-1325 (June 1980)	
	AP	SASAKI, K. <i>et al.</i> , "Expression cloning of a novel Gal $\beta$ (1-3/1-4)GlcNAc $\alpha$ 2,3-sialyltransferase using lectin resistance selection," <i>J. Biol. Chem.</i> , 268(30):22782-22787 (Oct. 25, 1993)	
	AQ	SAVAGE, B. <i>et al.</i> , "Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor," <i>Cell</i> , 84:289-297 (Jan. 26, 1996)	
	AR	SODETZ, J. <i>et al.</i> , "Carbohydrate on human factor VIII/von Willebrand factor," <i>J. Biol. Chem.</i> , 253(20):7202-7206 (Oct. 25, 1978)	
	AS	SODETZ, J. <i>et al.</i> , "Relationship of sialic acid to function and <i>in vivo</i> survival of human factor VIII/von Willebrand factor protein," <i>J. Biol. Chem.</i> , 252(15):5538-5546 (Aug. 10, 1977)	
	AT	WAGNER, D. <i>et al.</i> , "Initial glycosylation and acidic pH in the golgi apparatus are required for multimerization of von Willebrand factor," <i>J. Cell Biol.</i> , 102:1320-1324 (April 1986)	
	AU	WILKIE, A., "The molecular basis of genetic dominance," <i>J. Med. Genet.</i> , 31:89-98 (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.